New Weight-Loss shot enters first human tests
NCT ID NCT06737536
First seen Sep 30, 2025 · Last updated Jun 23, 2026 · Updated 33 times
Summary
This study tests a new medicine, NNC0662-0419, for people who are overweight or obese. It is the first time the drug is given to humans, so the main goal is to check safety and how the body handles it. About 100 adults aged 19-55 with a BMI between 27 and 40 will receive either the drug or a placebo as a weekly injection under the skin. The study lasts about 9 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Celerion, Lincoln
Lincoln, Nebraska, 68502, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NNC0662-0419
What this could lead to
If this early study shows the drug is safe, it could lead to a new weekly injection for weight management.
What could go wrong
This is a very early Phase 1 trial, the first time the drug is tested in humans. It is small and focused on safety, not weight loss. Many drugs fail at this stage.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.